Elicio Therapeutics reports preclinical AMP-DNA adjuvant study in Science Advances showing durable T-cell responses
PUBT · 3d ago
Share
Listen to the news
- Elicio Therapeutics reported preclinical results in a peer-reviewed Science Advances publication on its AMP-DNA adjuvant platform.
- Results have already been presented through the journal article, not a future conference or clinical readout.
- Studies showed stronger, longer-lasting immune responses than benchmark adjuvants, supporting broader use of the AMP platform beyond existing programs.
- Data in animal models, including non-human primates, suggest potential translational relevance for future oncology or infectious-disease development.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010800PRIMZONEFULLFEED9729011) on June 01, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved